Joseph R. Martel
Advanced in Late-Onset Retinal Degeneration

Dr. Joseph R. Martel

Ophthalmology
11216 Trinity River Dr., Suite H, 
Rancho Cordova, CA 
On Staff At
Accepting New Patients
Advanced in Late-Onset Retinal Degeneration
11216 Trinity River Dr., Suite H, 
Rancho Cordova, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joseph Martel is an Ophthalmologist in Rancho Cordova, California. Dr. Martel is rated as an Advanced provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Cataract, Diabetic Retinopathy, Interstitial Keratitis, and Glaucoma. Dr. Martel is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Wisconsin
Residency
University of Colorado
Specialties
Ophthalmology
Licenses
Ophthalmology in CA
Board Certifications
Ophthalmology - Board Certified
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

11216 Trinity River Dr., Suite H, Rancho Cordova, CA 95670

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Enrollment Status: Completed
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Betamethasone Sodium Phosphate
Study Phase: Phase 2
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: Combination of Mycophenolic Acid and Betamethasone Sodium Phosphate, Mycophenolic Acid, Restasis Ophthalmic Emulsion, Xiidra Ophthalmic Solution
Study Phase: Phase 2
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: February 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
Enrollment Status: Completed
Publish Date: January 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

8 Total Publications

Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
Journal: Eye & contact lens
Published: July 29, 2016
Similar Doctors
Elite in Late-Onset Retinal Degeneration
Dr. Glenn C. Yiu
Ophthalmology
Elite in Late-Onset Retinal Degeneration
Dr. Glenn C. Yiu
Ophthalmology

Regents Of The Univ Of Ca

2315 Stockton Blvd, 
Sacramento, CA 
 (11.2 miles away)
916-734-2011
Languages Spoken:
English
See accepted insurances

Glenn Yiu is an Ophthalmologist in Sacramento, California. Dr. Yiu is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, Vitrectomy, and Cataract Removal.

Elite in Late-Onset Retinal Degeneration
Dr. Ala Moshiri
Ophthalmology
Elite in Late-Onset Retinal Degeneration
Dr. Ala Moshiri
Ophthalmology

Regents Of The Univ Of Ca

4860 Y St, 
Sacramento, CA 
 (10.9 miles away)
916-734-8046
Languages Spoken:
English
See accepted insurances

Ala Moshiri is an Ophthalmologist in Sacramento, California. Dr. Moshiri is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Color Blindness, and Vitrectomy.

Elite in Late-Onset Retinal Degeneration
Dr. Susanna S. Park
Ophthalmology
Elite in Late-Onset Retinal Degeneration
Dr. Susanna S. Park
Ophthalmology

Regents Of The Univ Of Ca

4860 Y St, 
Sacramento, CA 
 (10.9 miles away)
Languages Spoken:
English
See accepted insurances

Susanna Park is an Ophthalmologist in Sacramento, California. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Late-Onset Retinal Degeneration. Her top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Vitrectomy, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martel's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile